Background Familial hypercholesterolemia (FH) is an autosomal dominant disease characterized by elevated plasma levels of LDL-cholesterol that confers an increased risk of premature atherosclerotic cardiovascular disease. Early identification and treatment of FH patients can improve prognosis and reduce the burden of cardiovascular mortality. Aim of this study was to perform the mutational analysis of FH patients identified through a collaboration of 20 Lipid Clinics in Italy (LIPIGEN Study). Methods We recruited 1592 individuals with a clinical diagnosis of definite or probable FH according to the Dutch Lipid Clinic Network criteria. We performed a parallel sequencing of the major candidate genes for monogenic hypercholesterolemia (LDLR, APOB, PCSK9, APOE, LDLRAP1, STAP1). Results A total of 213 variants were detected in 1076 subjects. About 90% of them had a pathogenic or likely pathogenic variants. More than 94% of patients carried pathogenic variants in LDLR gene, 27 of which were novel. Pathogenic variants in APOB and PCSK9 were exceedingly rare. We found 4 true homozygotes and 5 putative compound heterozygotes for pathogenic variants in LDLR gene, as well as 5 double heterozygotes for LDLR/APOB pathogenic variants. Two patients were homozygous for pathogenic variants in LDLRAP1 gene resulting in autosomal recessive hypercholesterolemia. One patient was found to be heterozygous for the ApoE variant p.(Leu167del), known to confer an FH phenotype. Conclusions This study shows the molecular characteristics of the FH patients identified in Italy over the last two years. Full phenotypic characterization of these patients and cascade screening of family members is now in progress.

Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study / A. Pirillo, K. Garlaschelli, M. Arca, M. Averna, S. Bertolini, C. Sebastiano, P. Tarugi, A.L. Catapano, M. Arca, M. Averna, S. Bertolini, C. Sebastiano, P. Tarugi, F. Pellegatta, F. Angelico, M. Arca, M. Averna, A. Bartuli, G. Biasucci, G. Biolo, L. Bonanni, K. Bonomo, C. Borghi, A.C. Bossi, A. Branchi, F. Carubbi, F. Cipollone, N. Citroni, M. Federici, C. Ferri, A.M. Fiorenza, A. Giaccari, F. Giorgino, O. Guardamagna, A. Iannuzzi, L. Iughetti, G. Lupattelli, G. Mandraffino, R. Marcucci, G. Mombelli, S. Muntoni, V. Pecchioli, C. Pederiva, A. Pipolo, L. Pisciotta, A. Pujia, F. Purrello, E. Repetti, P. Rubba, C. Sabbà, T. Sampietro, R. Sarzani, M.P. Tagliabue, C. Trenti, G.B. Vigna, J.P. Werba, S. Zambon, M.G. Zenti, A. Montali, D. Noto, S. Bertolini, C. Sebastiano, G. Fortunato, L. Grigore, M. Del Ben, M. Maranghi, A.B. Cefalù, P.S. Buonuomo, M.E. Capra, P. Vinci, S. D'Addato, S. Galbiati, F. Nascimbeni, M. Bucci, W. Spagnoli, I. Cardolini, N. Cervelli, C. Emanuela, V.A. Sun, L. Laviola, F. Bello, G. Chiariello, B. Predieri, D. Siepi, A. Saitta, B. Giusti, C. Pavanello, M. Lussu, L. Prati, G. Banderali, G. Balleari, T. Montalcini, R. Scicali, L. Gentile, M. Gentile, P. Suppressa, F. Sbrana, G. Cocci, A. Benso, E.A. Negri, O. Ghirardello, V. Lorenzo, A. Zambon, B. Enzo, I. Minicocci, R. Spina, C. Orlando, P. Tarugi, M.D. Di Taranto, M. Casula, L. Chiodo, K. Garlaschelli, E. Manzato, E. Tragni. - In: ATHEROSCLEROSIS SUPPLEMENTS. - ISSN 1567-5688. - 29(2017 Oct), pp. 17-24. [10.1016/j.atherosclerosissup.2017.07.002]

Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study

K. Garlaschelli
Secondo
;
A.L. Catapano
Ultimo
;
F. Pellegatta
Membro del Collaboration Group
;
A. Branchi;G. Mombelli
Membro del Collaboration Group
;
C. Pavanello
Membro del Collaboration Group
;
M. Casula
Membro del Collaboration Group
;
E. Tragni
Membro del Collaboration Group
2017

Abstract

Background Familial hypercholesterolemia (FH) is an autosomal dominant disease characterized by elevated plasma levels of LDL-cholesterol that confers an increased risk of premature atherosclerotic cardiovascular disease. Early identification and treatment of FH patients can improve prognosis and reduce the burden of cardiovascular mortality. Aim of this study was to perform the mutational analysis of FH patients identified through a collaboration of 20 Lipid Clinics in Italy (LIPIGEN Study). Methods We recruited 1592 individuals with a clinical diagnosis of definite or probable FH according to the Dutch Lipid Clinic Network criteria. We performed a parallel sequencing of the major candidate genes for monogenic hypercholesterolemia (LDLR, APOB, PCSK9, APOE, LDLRAP1, STAP1). Results A total of 213 variants were detected in 1076 subjects. About 90% of them had a pathogenic or likely pathogenic variants. More than 94% of patients carried pathogenic variants in LDLR gene, 27 of which were novel. Pathogenic variants in APOB and PCSK9 were exceedingly rare. We found 4 true homozygotes and 5 putative compound heterozygotes for pathogenic variants in LDLR gene, as well as 5 double heterozygotes for LDLR/APOB pathogenic variants. Two patients were homozygous for pathogenic variants in LDLRAP1 gene resulting in autosomal recessive hypercholesterolemia. One patient was found to be heterozygous for the ApoE variant p.(Leu167del), known to confer an FH phenotype. Conclusions This study shows the molecular characteristics of the FH patients identified in Italy over the last two years. Full phenotypic characterization of these patients and cascade screening of family members is now in progress.
APOB; familial hypercholesterolemia; LDLR; pathogenic variants; PCSK9; internal Medicine; cardiology and cardiovascular medicine
Settore BIO/14 - Farmacologia
ott-2017
Article (author)
File in questo prodotto:
File Dimensione Formato  
Atheroscler Suppl 2017_29_17.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 225.9 kB
Formato Adobe PDF
225.9 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/548038
Citazioni
  • ???jsp.display-item.citation.pmc??? 24
  • Scopus 62
  • ???jsp.display-item.citation.isi??? 55
social impact